Experienced in Fasciotomy

Dr. Martin S. Tallman

Hematology

675 N Saint Clair St, Galter 21-100,

Chicago, IL

41 Years of Experience

Experienced in Fasciotomy

675 N Saint Clair St, Galter 21-100,

Chicago, IL

OverviewInsuranceLocationsClinical Research

Overview

Martin Tallman is a Hematologist in Chicago, Illinois. Dr. Tallman has been practicing medicine for over 41 years and is rated as an Experienced provider by MediFind in Fasciotomy. His top areas of expertise are Acute Promyelocytic Leukemia, Acute Myeloid Leukemia (AML), Hairy Cell Leukemia (HCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 411 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Fasciotomy.

Specialties

Hematology

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Humana

HMO
INDEMNITY
POS
PPO

Locations

675 N Saint Clair St, Galter 21-100, Chicago, IL 60611

Call: 312-695-0990

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)

Enrollment Status: Enrolling_by_invitation

Publish Date: October 07, 2025

Intervention Type: Drug

Study Drug: Ceramide NanoLiposome

Study Phase: Phase 1

A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)

Enrollment Status: Active_not_recruiting

Publish Date: April 11, 2025

Intervention Type: Other

Study Phase: Not Applicable

Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)

Enrollment Status: Completed

Publish Date: December 13, 2024

Intervention Type: Drug, Other, Procedure

Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine

Study Phase: Phase 3

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Enrollment Status: Terminated

Publish Date: July 29, 2024

Intervention Type: Drug

Study Drug: Uproleselan

Study Phase: Phase 3

A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy

Enrollment Status: Completed

Publish Date: July 27, 2023

Intervention Type: Drug

Study Drug: Cytarabine

Study Phase: Phase 2

Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML

Enrollment Status: Terminated

Publish Date: February 08, 2023

Intervention Type: Drug

Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim

Study Phase: Phase 3

A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia

Enrollment Status: Terminated

Publish Date: February 26, 2020

Intervention Type: Drug

Study Phase: Phase 1

An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia

Enrollment Status: Completed

Publish Date: September 27, 2018

Intervention Type: Biological

Study Phase: Phase 2

View 7 Less Clinical Trials

412 Total Publications

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.

Journal: Cancer

Published: May 20, 2025

View All 412 Publications

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tallman's expertise for a condition

ConditionClose